quarter conference Great. Thank second welcome, you, call. our and to Kim, everyone,
COVID rates. successfully maintaining China by a in CooperSurgical we're to share of our start continuing managing highlighting businesses and performing and gained We're chain and market-leading from posted strong supply variety me Let growth, CooperVision our through momentum. growth to challenges see well. revenue restrictions are extremely that strong Both are
the year So I'm progressing. is pleased with really how
both incorporating continuing see. businesses For organic year, QX guidance the and we're increasing our our to by strength outperformance we're for revenue the full
products CooperSurgical led strength at revenues or organically. $XXX Consolidated as XX% up $XXX all-time but daily and which growth our hydrogel reported details, quarter. quarter and CooperVision's high share silicone provide business. at million, management impacted contact will CooperVision up by reached million, by $XXX quarter was XX% the per in solutions million, in negatively quarter. the portfolio with Brian was were our organically myopia up CooperSurgical's another and this an to X% posted $X.XX, fertility Moving of Non-GAAP double-digit FX and earnings lens The business,
Moving to on all reporting CooperVision and organic percentages basis. an
resulted as X%, The Our Pac in those within torics nice revenue categories, we we EMEA organic growth you And diversified up estimate XX%. strong This spheres, growth for multifocals was impressive all rate XX% Americas performance. against strong and were of and grew regions. is in share geographic X and product XX%. Asia nicely grew all the which quarters, our calendar QX calendar grew our XX% tracking market QX following was gains, grew
numbers, new relationships well customer on remain flexibility strong we positioned gaining product our execute to we continue and as and key market-leading provide service. products, So expand through offerings, account fantastic ranges, deliver customized share launch
strong very lenses silicones growing daily broadest results, the to we Regarding products, the in and Daily the posted lead our portfolio silicone industry. hydrogel continue market, XX%. offer
through we is remain categories launch spheres worn. in best of of lens about our MyDay, effect nice MyDay but is very markets it's they've rapidly halo all the The optometrists range MyDay to multifocal year. it's binocular the out brand. a progress on multifocal. breakthrough on this well, our ever torics, This still available, we'll continuing The already from the on taking is while Our and we so broad patients system future the geographically, progressive available are and highlighting fitting remains multifocals. X-day spheres, torics share as limited worth And continue and also is premium are a rolling it's these feedback successful it the optimistic success fantastic, offering, multifocal where of the driving say and performing
silicone available multifocal portfolio roll and hydrogel as in our mass is well region, which our other toric Japan. The especially to of sold quarter, year and out also we're market This sphere, is lens clariti, a in is this more Pac this into where setting. again Asia performed brand continuing really daily a typically in
lastly, comment FRPs, happy to and all solid sales. branded Avaira these our about X% offerings, in that as Biofinity the silicone And another growth report we're umbrella Our of quarter of reported rate an product uptick growth. I'm an seeing
our you are lot own brands also take of aware, customer showing includes which many MyDay. As customized a brands, we especially growth, high-quality strong CooperVision in are offerings, our of pride but
practitioners. to myopia including We healthy, strength million, our driven $XX management. posted by part up of The Moving growing up revenues in XXX%. XX%, private business MiSight of extremely is accounts continued key and with specialty traction
our customers some selling where is MiSight, particular, segment lenses. sales and their our continues halo market. hurting another who restrictions seeing And management also growing note, other the encouraging geographies excelling world the of well. are COVID but are the with tracking is of selling China, all to positive ortho-k our on our accelerating the in the data trends launch we're of as We MiSight in really embrace community rest myopia have are challenges MiSight in performing showing impacting ophthalmic
myopia EssilorLuxottica seeing product management in and venture exciting SightGlass, with additional glasses. closed markets of the in additional availability joint we're such China. to We our already March, and including as progress, Moving
we right sharing SightGlass FDA in the with data the FDA is and an compiled now, clinical the receiving near future. data Regarding it approval, the to for and look forward X-year being
management, results. we're and strong in momentum summary, to posting myopia we all So of areas seeing in strong expect continue
touch our Recent Before a supply decline this moving significant and to hard, solutions market we've operation business. data, have in let me contact challenges on hit lens experienced sales.
facility. declining industry business going that's require to of a strategic completed a we in upgrade this a a confirmed this, is lot Given review and to the nonstrategic capital
by down last million we exit financial $XX So year-end. year. business perspective, roughly we fiscal the this $XX a revenues decided expect to from business From this report in million to year,
market from are our childhood these of lens rates and wrap exceptionally additional to is in the patient on rest to Brian of contact P&L minutes. the well, and even CooperVision, tied and Growth the comparability, will ensure are performing traffic up challenges. increasing We transparency in silicones provide the To COVID. of face results growth the a color excluding lower on offsetting daily in organic few prevalence COVID continuing an myopia
continues is as should vision expect supported Growth We of global in strong season that traffic that patient to and we increase look this fall. also and a growth XX% the to correction, including expected macro remain today back-to-school to trends the strong what by to myopic by is is improve, industry to X/X world be the XXXX. forward roughly around
fast-growing our CooperVision, robust ongoing business, product For very a data launches, myopia have and management portfolio, product strong. remains fit a we
So our we future. remain bullish very on
Moving to CooperSurgical. We in by posted growth fertility another led strong double-digit our business. quarter
these, our with other to IUD equipment, rebounded also start $XXX from along up activity. Our business strength with growth, as unexpected me by portfolio Strength believe million, product testing, the throughout our and that of We COVID posted fast their returned medical as genomics seen but areas. posted capital lab comprise strength was some market, in storage was clinics AI-based transfer. device a to embryo our which Witness OB/GYN lab RI cell select stem optimizing XX%. and donor ag practices weakness used Particular of proprietary safety management which consumables, seen let our implement track doctors security fertility. best PARAGARD, to portfolio quarter. hasn't through broader our automated did genetic maximize system each our products, performance from Fertility and the sales which Walking solid from have of
X%. Moving posted to surgical our $XXX down million, and category. of office sales We
strong we most and our portfolio given X%, Our Particular impacted is closure supply strength within by business OB/GYN seen this this devices medical and unit area the grew was laparoscopic challenges. labor where were delivery which products. chain global in was
is sales have commercial grew they going exciting that some to ton now X%. seeing additional drive There early business synergies. the activity to growth and of cell are Moving entered The with we on integrating business it's our and CooperSurgical, ideas Generate storage teams stem a into synergies, well. acquisition, success this right
bullish on in this I our remain future So space.
continuing wrap Lastly, up control move a pre-COVID end pressure closely patient telemedicine. entire in the with on PARAGARD. see CooperSurgical, softness remain market for few doesn't what we're me levels we'll the the the and is volumes flow let a to by in see as under shift the pills takeaways. behavior Sales lower we optimistic buying year. appear and to monitoring market. the driven This certainly were of has To temporary key we and quarter, towards down remained with lower we a product-specific X% return to be IUD birth believe to cautiously as highlight on We're marketplace
we're that synergies a certainly First, is parts fertility we're on, Generate from looking cell success There the commercial the now. right on success storage capitalizing acquisition, this and of of seeing stem a and both are acquisition lot our business. like
growth of X% and upper perform Second, strong This market of macro our we the industry part growth to fertility us is with range. a to that with continues forecasting extremely trends, solid business continue well. long-term in XX%
integrating customer conclude, they've last completed trends. and businesses these To our in the market-leading managing challenges, significant beginning chain has with macro industries Lastly, while of team operate service strong strong supply X and since and we performance. even and impressive acquisitions so fiscal logistics recession-resistant sales growth year, through maintained
our sales amounts significant of annuity Additionally, in nature. are
on investing several to ESG growth our our dedication didn't facing ESG be employees. progress can remain Cooper released special value. lastly, while the maintaining in focus to such times a drives which if on So our It's advancing resilient managing highlights you delivering sensitive growth. shareholder our important I We'll be progress like and long-term ensuring areas, we're in find a and report, intelligently initiatives. we success make This report continuing their and Relations this, on We I'd remiss to our makes projects our And this on to thank place infrastructure our be page. and work. includes hard fantastic need us to proactive that just Investor to second challenges capitalize work businesses, support our opportunities
over call Brian. I'll the Cooper So employees. a big all thank that, to to with And turn you